Effective combination treatment with imatinib requires residual Bcr-Abl-inhibition in imatinib-resistant cell lines.

被引：0
|
作者：
La Rosee, P
Johnson, K
Corbin, AS
Stoffregen, EP
Melo, JV
Hochhaus, A
Deininger, MW
Druker, BJ
机构：
[1] Univ Heidelberg, Fak Klin Med Mannheim, Med Klin 3, D-6800 Mannheim, Germany
[2] Oregon Hlth Sci Univ, Oregon Canc Inst, Portland, OR 97201 USA
[3] Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Dept Hematol, London, England
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
58
引用
收藏
页码：19A / 20A
页数：2
相关论文
共 50 条
  • [1] Activity of Ras-MAPK signaling in imatinib-resistant BCR/ABL-positive cell lines.
    Miyoshi, T
    Nagai, T
    Ohmine, K
    Tarumoto, T
    Mano, H
    Komatsu, N
    Ozawa, K
    BLOOD, 2002, 100 (11) : 329B - 329B
  • [2] In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines
    La Rosée, P
    Johnson, K
    Corbin, AS
    Stoffregen, EP
    Moseson, EM
    Willis, S
    Mauro, MM
    Melo, JV
    Deininger, MW
    Druker, BJ
    BLOOD, 2004, 103 (01) : 208 - 215
  • [3] A MEK1/2 inhibitor U0126 restores the sensitivity to imatinib in the imatinib-resistant BCR-ABL expressing cell lines
    Miyoshi, T
    Nagai, T
    Ohmine, K
    Nakamura, M
    Tarumoto, T
    Kano, Y
    Komatsu, N
    Ozawa, K
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 231 - 231
  • [4] The combination of imatinib and a farnesyltransferase inhibitor, R115777, causes strong synergistic growth inhibition by enhancement of apoptosis in imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cell lines.
    Miyoshi, T
    Nagai, T
    Ohmine, K
    Nakamura, M
    Kano, Y
    Komatsu, N
    Ozawa, K
    BLOOD, 2003, 102 (11) : 319B - 319B
  • [5] Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    Weisberg, Ellen
    Manley, Paul W.
    Cowan-Jacob, Sandra W.
    Hochhaus, Andreas
    Griffin, James D.
    NATURE REVIEWS CANCER, 2007, 7 (05) : 345 - U5
  • [6] Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    Ellen Weisberg
    Paul W. Manley
    Sandra W. Cowan-Jacob
    Andreas Hochhaus
    James D. Griffin
    Nature Reviews Cancer, 2007, 7 : 345 - 356
  • [7] Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells
    Tolomeo, Manlio
    Grimaudo, Stefania
    Di Cristina, Antonietta
    Pipitone, Rosaria M.
    Dusonchet, Luisa
    Meli, Maria
    Crosta, Lucia
    Gebbia, Nicola
    Invidiata, Francesco Paolo
    Titone, Lucina
    Simoni, Daniele
    CANCER LETTERS, 2008, 265 (02) : 289 - 297
  • [8] Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors
    Radujkovic, Aleksandar
    Topaly, Julian
    Fruehauf, Stefan
    Zeller, W. Jens
    ANTICANCER RESEARCH, 2006, 26 (3A) : 2169 - 2177
  • [9] Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
    Oaxaca, Derrick M.
    Yang-Reid, Sun Ah
    Ross, Jeremy A.
    Rodriguez, Georgialina
    Staniswalis, Joan G.
    Kirken, Robert A.
    TUMOR BIOLOGY, 2016, 37 (09) : 12643 - 12654
  • [10] Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
    Redaelli, Sara
    Piazza, Rocco
    Rostagno, Roberta
    Magistroni, Vera
    Perini, Pietro
    Marega, Manuela
    Gambacorti-Passerini, Carlo
    Boschelli, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 469 - 471
12345